- Stem cell transplant is the only potential cure, however it is high risk and not an option for most patients4
- Challenges facing current standard-of-care therapies include poor overall survival (OS), limited duration of response, and singular mechanistic action5-8
- Nontransplant options only prolong survival by months and the risk of death remains high6,8
- Responses achieved with currently available treatment are often <1 year duration6,7
- These therapies focus on either decreasing leukemic proliferation or limiting immune activation, but do not do both5,9-11
- Many patients require blood transfusions for cytopenias and are at risk for hospitalization12
Patient characteristics and management options of HR-MDS and AML are often similar7,13-15
Significant treatment innovations are lacking1,2
The risk of death and transformation to AML remain high,
Most innovations have been limited to specific driver mutations1-3
Despite recent advances, overall survival is <1 year13-15
Learn more about the role of TIM-3
*For AML, lower-intensity regimens for unfit patients can include low-dose cytarabine. For HR-MDS, lower-intensity regimens are based on hypomethylating agents.
AML, acute myeloid leukemia; HR-MDS, high-risk myelodysplastic syndrome; TIM-3, T cell immunoglobulin and mucin domain-3.